Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients

What Was Tested

The paper reports a study of Teduglutide (GLP-2 analog), published as a clinical trial.

Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant GLP-2 analogue, prolongs the intestinotrophic properties of GLP-2 in animal models.

The safety and effect of teduglutide were investigated in SBS patients with and without a colon in continuity.

Who Took Part

According to the abstract, 16 patients were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Nutrient balance studies, D-xylose tests, and intestinal mucosa biopsies were performed at baseline, on the last three days of treatment, and after three weeks of follow up.

How the Study Was Run

In design terms this was a pilot study.

It is described as a pilot, a small early test of whether a larger Teduglutide (GLP-2 analog) study would be practical.

The methods mention a period of three weeks.

What Was Measured

Topics PubMed links to this paper include Colon, Gastrointestinal Agents, Glucagon-Like Peptide 2, Glucagon-Like Peptides, Intestinal Absorption, Jejunostomy and Jejunum.

What This Means in Plain Language

The paper is a pilot study of Teduglutide (GLP-2 analog) in 16 patients over three weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2005 (Gut), a journal based in England.

More context: the Teduglutide (GLP-2 analog) compound page.